- Home
- APLM vs LUCY Comparison
APLM vs LUCY Comparison
Compare APLM & LUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- LUCY
- Stock Information
- Founded
- APLM 2016
- LUCY 2017
- Country
- APLM United States
- LUCY United States
- Employees
- APLM N/A
- LUCY N/A
- Industry
- APLM Blank Checks
- LUCY Ophthalmic Goods
- Sector
- APLM Finance
- LUCY Health Care
- Exchange
- APLM Nasdaq
- LUCY Nasdaq
- Market Cap
- APLM 15.6M
- LUCY 18.5M
- IPO Year
- APLM N/A
- LUCY 2022
- Fundamental
- Price
- APLM $7.89
- LUCY $5.55
- Analyst Decision
- APLM Strong Buy
- LUCY Strong Buy
- Analyst Count
- APLM 2
- LUCY 1
- Target Price
- APLM $425.00
- LUCY $20.00
- AVG Volume (30 Days)
- APLM 106.0K
- LUCY 53.0K
- Earning Date
- APLM 08-14-2024
- LUCY 11-12-2024
- Dividend Yield
- APLM N/A
- LUCY N/A
- EPS Growth
- APLM N/A
- LUCY N/A
- EPS
- APLM N/A
- LUCY N/A
- Revenue
- APLM $2,101,000.00
- LUCY $1,561,506.00
- Revenue This Year
- APLM N/A
- LUCY $68.16
- Revenue Next Year
- APLM N/A
- LUCY $636.84
- P/E Ratio
- APLM N/A
- LUCY N/A
- Revenue Growth
- APLM 70.54
- LUCY 158.62
- 52 Week Low
- APLM $6.50
- LUCY $3.26
- 52 Week High
- APLM $105.00
- LUCY $27.20
- Technical
- Relative Strength Index (RSI)
- APLM 42.42
- LUCY 37.26
- Support Level
- APLM $7.70
- LUCY $5.74
- Resistance Level
- APLM $8.88
- LUCY $6.61
- Average True Range (ATR)
- APLM 1.34
- LUCY 0.51
- MACD
- APLM -0.04
- LUCY -0.07
- Stochastic Oscillator
- APLM 24.77
- LUCY 0.00
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.